Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.090
+0.130 (4.39%)
May 5, 2026, 4:00 PM EDT - Market closed
Xenetic Biosciences Revenue
In the year 2025, Xenetic Biosciences had annual revenue of $2.98M with 19.04% growth. Xenetic Biosciences had revenue of $766.30K in the quarter ending December 31, 2025, with 18.11% growth.
Revenue (ttm)
$2.98M
Revenue Growth
+19.04%
P/S Ratio
2.38
Revenue / Employee
$1,488,206
Employees
2
Market Cap
7.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | 476.13K | 19.04% |
| Dec 31, 2024 | 2.50M | -39.71K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.24K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | 17.07K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 7.59M | 4.59M | 152.83% |
| Dec 31, 2016 | 3.00M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 1.00M | 706.40K | 240.60% |
| Dec 31, 2012 | 293.60K | - | - |
| Aug 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| BioAtla | 2.00M |
| Can-Fite BioPharma | 405.00K |
| Addex Therapeutics | 218.17K |
| Silo Pharma | 72.10K |
| Alaunos Therapeutics | 5.00K |
XBIO News
- 13 days ago - Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting - Accesswire
- 7 weeks ago - Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Accesswire
- 4 months ago - Xenetic Biosciences Transcript: AGM 2025 - Transcripts
- 5 months ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 6 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 9 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire